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Background: Although not an approved therapy, nebulised hypertonic saline (HS)
is widely used in CF. Based largely on a single study, various consensus guidelines
provide qualiﬁed support for HS using 7% b.i.d., but not at a lower concentration or
frequency [1]. We sought to gain an understanding of patterns of HS use in a large
cross-section of CF physicians.
Methods: Specialist physicians in the USA, UK and the EU, currently treating respi-
ratory disease in 20 patients (ages 6+) suffering from CF were asked to participate.
Consenting physicians were asked to complete a questionnaire regarding use of HS in
their patients with CF.
Results: 200 physicians in the USA, UK, and EU were recruited. Collectively, these
clinicians had a case-load of 10,600 patients with CF (18 years = 77%). Most
physicians used HS although the proportion of patients treated varied by region from
30% to 53% and HS concentrations ranged from <3% to >10%. The highest use of
3% HS was in the USA (50%). In the EU overall, 40% patients were administered
6−7% HS concentrations irrespective of treatment frequency, 46% patients had therapy
prescribed b.i.d. irrespective of HS concentrations and 16% pts were prescribed at least
6% HS b.i.d.
Table: Patterns of hypertonic saline use
Country USA UK France Germany Italy Spain Other EU
Number of physicians per region 50 20 20 20 20 20 50
Doctors using HS at all 98% 95% 80% 85% 90% 95% 62%
Mean % CF patients (age 6+)
currently treated using HS 51% 41% 30% 34% 52% 53% 37%
using HS as an acute treatment 25% 37% 67% 64% 73% 36% 59%
using HS as a chronic treatment 84% 70% 82% 74% 54% 82% 100%
Conclusions: This large survey of HS in patients with CF has conﬁrmed that HS is
widely at a range of concentrations and frequencies, primarily as chronic therapy. This
study did not explore the basis of the differences in use and it is unclear if further
standardisation of dosing strategies is required or warranted.
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Objectives: The objective of this study was to assess the compliance of a multidis-
ciplinary cystic ﬁbrosis (CF) clinic at a tertiary paediatric centre with international
best practice guidelines and compare with international data.
Methods: We compared the percentage of cases attending our CF clinic that
complied with 7 clinical care guidelines recommended by the CF Foundation (CFF)
(USA). We then compared our results to data reported by the CFF. We also assessed
adequacy of clinic consultations with members of the multidisciplinary CF team as
recommended by the CF Trust (UK).
Results: The percentage of the 90 patients attending our centre who met guidelines
was similar or superior to the ﬁgures reported by the CFF in 2010 as follows;
4 clinic visits 98% (vs 63% CFF), 4 respiratory cultures 95% (vs 45% CFF),
2 pulmonary function tests if 6 years old 98% (vs 82%), inﬂuenza vaccine
if 6 months old 96% (vs 73% CFF), fat-soluble vitamin levels measured 94%
(vs 81% CFF), oral glucose tolerance test if 10 years old 94% (vs 19% CFF) and
serum liver enzyme measurement 94% (vs 72% CFF).
The vast majority of patients received consultations with the multidisciplinary
CF team as recommended by the CF Trust as follows: full care patients reviewed
every 3 months by CF nurse specialist (95%), physiotherapist (85%), dietician (94%)
as well as access at each clinic to a clinical psychologist (91%) and social
worker (88%) if needed. Our clinic does not however have routine access to a
specialist CF pharmacist.
Conclusion: The majority of patients attending a tertiary paediatric CF clinic in
this study receive care in accordance with international best practice guidelines.
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Introduction: To overcome the shortage of organs, in 2008, our center has used
non-heart-beating donors (NHBD) in lung transplantation. In this study, we assess
the evolution of cystic ﬁbrosis patients by source of the organ.
Methods and Results: Since 2008, 17 patients with cystic ﬁbrosis underwent
double lung transplant. Three of these patients received lungs from NHBD donors.
The other 14 received organs from brain-dead donors (BD). Age and gender of
recipients and donors was equivalent in both groups. The PaO2/FiO2 ratio was
better in the BD group (499 vs 357, p = 0.01). Cold ischemic time did not differ
in both groups (181 minutes for the ﬁrst lung and 275min for the second lung
in the BD group vs 194min and 298min in the NHBD group, p = 0.72 and 0.57
respectively). Operating bleeding is equivalent in both groups (p = 0.69). We do
not observe a signiﬁcant difference in the duration of intubation despite a trend of
longer duration of intubation in the BD group (90 h vs 39 h, p = 0.73) or for the
stay in intensive care and hospitalization. Changes in lung function at 1, 3, 6 and
12 months are equivalent in both groups.
Conclusion: The lungs harvested from non-heart-beating donors seem to behave
the same way as those of BD donors in medium term. But patients with cystic
ﬁbrosis are a young population with a high life expectancy. The long-term results
of transplantation of these organs are to follow.
